Surrozen, Inc./DE Proceeds from Sale and Maturity of Marketable Securities
Surrozen, Inc./DE (SRZN) reported Proceeds from Sale and Maturity of Marketable Securities of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities · last filed 2025-03-31
- Surrozen, Inc./DE proceeds from sale and maturity of marketable securities for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- Surrozen, Inc./DE proceeds from sale and maturity of marketable securities for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- Surrozen, Inc./DE proceeds from sale and maturity of marketable securities for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- Surrozen, Inc./DE proceeds from sale and maturity of marketable securities for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- Surrozen, Inc./DE proceeds from sale and maturity of marketable securities for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Surrozen, Inc./DE proceeds from sale and maturity of marketable securities for fiscal 2023 was $80.17M, a 16.80% increase from fiscal 2022.
- Surrozen, Inc./DE proceeds from sale and maturity of marketable securities for fiscal 2022 was $68.64M, a 383.36% increase from fiscal 2021.
- Surrozen, Inc./DE proceeds from sale and maturity of marketable securities for fiscal 2021 was $14.20M.
| Period end | Proceeds from Sale and Maturity of Marketable Securities 3 month | Proceeds from Sale and Maturity of Marketable Securities 6 month | Proceeds from Sale and Maturity of Marketable Securities 9 month | Proceeds from Sale and Maturity of Marketable Securities 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $0.00 derived: sum of 2 quarters · filed 2025-03-31 | $0.00 derived: sum of 3 quarters · filed 2025-03-31 | $0.00 10-K · filed 2025-03-31 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $0.00 derived: sum of 2 quarters · filed 2024-11-06 | $0.00 10-Q · filed 2024-11-06 | $9.50M derived: sum of 4 quarters · filed 2025-03-31 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $0.00 10-Q · filed 2024-08-12 | $9.50M derived: sum of 3 quarters · filed 2025-03-31 | $26.50M derived: sum of 4 quarters · filed 2025-03-31 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-08 | $9.50M derived: sum of 2 quarters · filed 2025-03-31 | $26.50M derived: sum of 3 quarters · filed 2025-03-31 | $54.66M derived: sum of 4 quarters · filed 2025-03-31 |
| 2023-12-31 | $9.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $26.50M derived: sum of 2 quarters · filed 2025-03-31 | $54.66M derived: sum of 3 quarters · filed 2025-03-31 | $80.17M 10-K · filed 2025-03-31 |
| 2023-09-30 | $17.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $45.16M derived: sum of 2 quarters · filed 2024-11-06 | $70.67M 10-Q · filed 2024-11-06 | $81.43M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $28.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $53.66M 10-Q · filed 2024-08-12 | $64.43M derived: sum of 3 quarters · filed 2024-08-12 | $108.30M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $25.50M 10-Q · filed 2024-05-08 | $36.27M derived: sum of 2 quarters · filed 2024-05-08 | $80.14M derived: sum of 3 quarters · filed 2024-05-08 | $94.14M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $10.77M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-10 | $54.64M derived: sum of 2 quarters · filed 2024-04-10 | $68.64M derived: sum of 3 quarters · filed 2024-04-10 | $68.64M 10-K · filed 2024-04-10 |
| 2022-09-30 | $43.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $57.87M derived: sum of 2 quarters · filed 2023-11-08 | $57.87M 10-Q · filed 2023-11-08 | $58.97M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $14.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $14.00M 10-Q · filed 2023-08-09 | $15.10M derived: sum of 3 quarters · filed 2023-08-09 | $19.50M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-10 | $1.10M derived: sum of 2 quarters · filed 2023-05-10 | $5.50M derived: sum of 3 quarters · filed 2023-05-10 | |
| 2021-12-31 | $1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $5.50M derived: sum of 2 quarters · filed 2023-03-31 | $14.20M 10-K · filed 2023-03-31 | |
| 2021-09-30 | $4.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $13.10M 10-Q · filed 2022-11-14 | ||
| 2021-06-30 | $8.70M 10-Q · filed 2022-08-11 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $0.00 10-K · filed 2022-03-28 | ||
| 2020-09-30 | $0.00 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |